Immune Requirements of Post-Exposure Immunization with Modified Vaccinia Ankara of Lethally Infected Mice
Open Access
- 11 March 2010
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (3), e9659
- https://doi.org/10.1371/journal.pone.0009659
Abstract
Current prophylactic vaccines work via the induction of B and T cell mediated memory that effectively control further replication of the pathogen after entry. In the case of therapeutic or post-exposure vaccinations the situation is far more complex, because the pathogen has time to establish itself in the host, start producing immune-inhibitory molecules and spread into distant organs. So far it is unclear which immune parameters have to be activated in order to thwart an existing lethal infection. Using the mousepox model, we investigated the immunological mechanisms responsible for a successful post-exposure immunization with modified vaccinia Ankara (MVA). In contrast to intranasal application of MVA, we found that intravenous immunization fully protected mice infected with ectromelia virus (ECTV) when applied three days after infection. Intravenous MVA immunization induced strong innate and adaptive immune responses in lethally infected mice. By using various gene-targeted and transgenic mouse strains we show that NK cells, CD4 T cells, CD8 T cells and antibodies are essential for the clearance of ECTV after post-exposure immunization. Post-exposure immunization with MVA is an effective measure in a murine model of human smallpox. MVA activates innate and adaptive immune parameters and only a combination thereof is able to purge ECTV from its host. These data not only provide a basis for therapeutic vaccinations in the case of the deliberate release of pathogenic poxviruses but possibly also for the treatment of chronic infections and cancer.Keywords
This publication has 55 references indexed in Scilit:
- Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE® against aerosolized rabbitpox virus in a rabbit modelVaccine, 2009
- Impaired Antibody Response Causes Persistence of Prototypic T Cell–Contained VirusPLoS Biology, 2009
- Modified Vaccinia Virus Ankara Triggers Chemotaxis of Monocytes and Early Respiratory Immigration of Leukocytes by Induction of CCL2 ExpressionJournal of Virology, 2009
- Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapiesVirology, 2009
- Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protectionJCI Insight, 2008
- Induction of Natural Killer Cell Responses by Ectromelia Virus Controls InfectionJournal of Virology, 2007
- CD127+CCR5+CD38+++CD4+Th1 Effector Cells Are an Early Component of the Primary Immune Response to Vaccinia Virus and Precede Development of Interleukin-2+Memory CD4+T CellsJournal of Virology, 2006
- Obligatory Requirement for Antibody in Recovery from a Primary Poxvirus InfectionJournal of Virology, 2006
- Protective Immunity against Secondary Poxvirus Infection Is Dependent on Antibody but Not on CD4 or CD8 T-Cell FunctionJournal of Virology, 2006
- Splenic T Zone Development Is B Cell DependentThe Journal of Experimental Medicine, 2001